Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009
- 1 September 2011
- journal article
- research article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 17 (9) , 1352-1355
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsClinical Infectious Diseases, 2010
- Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsAIDS, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Genotypic Resistance Profile and Clinical Progression of Treatment-Experienced HIV Type 1-Infected Patients with Virological FailureAIDS Research and Human Retroviruses, 2008
- Frequency and Treatment‐Related Predictors of Thymidine‐Analogue Mutation Patterns in HIV‐1 Isolates after Unsuccessful Antiretroviral TherapyThe Journal of Infectious Diseases, 2006
- Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmissionAIDS, 2006
- Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) TrialsClinical Infectious Diseases, 2006
- Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2003
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998